Links
- ORCID
- ORCID
- ORCID
- ORCID
- ORCID
- ORCID
- Crossref | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.manchester.ac.uk]
- [www.manchester.ac.uk]
- [archive-ouverte.unige.ch] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [link.springer.com] | PDF
Tools
A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease
,
Stephen F. Carter,
Carter Sf ,
Juha Rinne,
Alexander Drzezga,
David J. Brooks,
Brooks Dj,
Rik Vandenberghe ,
Daniela Perani,
Anton Forsberg,
Bengt Långström,
Noora Scheinin,
Kjell Nagren,
Mira Karrasch ,
Kjell Någren
and other authors.
Abstract
PURPOSE: Amyloid PET tracers have been developed for in vivo detection of brain fibrillar amyloid deposition in Alzheimer's disease (AD). To serve as an early biomarker in AD the amyloid PET tracers need to be analysed in multicentre clinical studies. METHODS: In this study 238 [(11)C]Pittsburgh compound-B (PIB) datasets from five different European centres were pooled. Of these 238 datasets, 18 were excluded, leaving [(11)C]PIB datasets from 97 patients with clinically diagnosed AD (mean age 69 +/- 8 years), 72 patients with mild cognitive impairment (MCI; mean age 67.5 +/- 8 years) and 51 healthy controls (mean age 67.4 +/- 6 years) available for analysis. Of the MCI patients, 64 were longitudinally followed for 28 +/- 15 months. Most participants (175 out of 220) were also tested for apolipoprotein E (ApoE) genotype. RESULTS: [(11)C]PIB retention in the neocortical and subcortical brain regions was significantly higher in AD patients than in age-matched controls. Intermediate [(11)C]PIB retention was observed in MCI patients, with a bimodal distribution (64 % MCI PIB-positive and 36 % MCI PIB-negative), which was significantly different the pattern in both the AD patients and controls. Higher [(11)C]PIB retention was observed in MCI ApoE epsilon4 carriers compared to non-ApoE epsilon4 carriers (p